Drug intelligence / Profile preview

CTP-0303

Development stage: Phase 3
Lead developer: Taejoon Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

CTP-0303 is an investigational drug developed by Taejoon Pharmaceutical. Its primary indication is for the treatment of chronic and debilitating diseases where current treatment options are insufficient or limited[1][2]. In at least one clinical trial, CTP-0303 has been studied as a bowel preparation agent, suggesting its use in gastrointestinal procedures[4]. The precise mechanism of action and molecular target have not been disclosed in publicly available sources as of April 2025.

Other names: Taejoon bowel preparation

Beyond the preview

Go deeper on CTP-0303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTP-0303.

Explore the full profile